Corporate ProfileNantHealth is a next-generation, evidence-based, personalized healthcare company enabling improved patient outcomes and more effective treatment decisions for critical illnesses. NantHealth‘s unique systems-based approach to personalized healthcare integrates novel diagnostics with large-scale, biometric and phenotypic data to track patient outcomes and deliver precision medicine. In addition, NantHealth’s adaptive learning system, CLINICS, continuously improves decision-making and further optimizes our clinical pathways and decision algorithms over time.
Stock Quote NH (Common Stock) $13.20 + 0.17 (1.30%)
Today's Open$12.96
Previous Close$13.03
Data as of 10/27/16 11:59 a.m. ET
Refresh quote

Data provided by Nasdaq. Minimum 15 minutes delayed.

Stock Chart
Stock chart for: NH.O.  Currently trading at $13.20 with a 52 week high of $21.00 and a 52 week low of $9.79.
Recent News

October 26, 2016

NantHealth Announces Immunotherapy Clinical Trials in the Mid-Atlantic, First Whole Genomics Supercomputing Medical Reasoning Engine Helps Oncologists Make Informed Treatment Decisions for Cancer Patients

Horizon Blue Cross Blue Shield, New Jersey’s largest health insurance plan, to reimburse for GPS CancerTM comprehensive molecular test in investigational cancer studies for certain lung, breast and colon cancers The supercomputing genomics engine, a decade in the making, has successfully completed analyses of more than 21,000 cancer tissue samples analyzed for whole genome, whole exome and RNA from more than 7,000 unique patients with mult...

Read More >

September 21, 2016

NantHealth Partners with Children’s Hospital of Orange County to Revolutionize Pediatric Cancer Care Through the Use of GPS Cancer™

GPS Cancer will allow physicians to identify personalized treatments for children with rare, refractory or recurrent cancers for whom conventional approaches have proven unsuccessful Research partnership will provide new hope for an estimated 15,780 children between the ages of birth and 19 years of age who are diagnosed with cancer each year1 CULVER CITY, Calif.--(BUSINESS WIRE)--Sep. 21, 2016-- In an effort to accelerate and improve ...

Read More >

September 07, 2016

Phoenix Children’s Hospital Selects NantHealth’s Molecular Testing Platform and Comprehensive Suite of Software Solutions for Precision Cancer Care

One of the nation’s leading pediatric hospitals to adopt GPS Cancer™, a comprehensive molecular testing platform for personalized cancer therapy, for its patients and self-insured employee population NantHealth’s decision support, patient engagement, care coordination, and analytics solutions to help Phoenix Children’s advance population health and improve value-based outcomes CULVER CITY, Calif.--(BUSINESS WIRE)--Sep. 7, 2016-- ...

Read More >

Upcoming Events
There are currently no events scheduled.